VALIANT (2025) — Trial Summary

VALIANT (2025): The VALIANT phase 3 trial evaluated pegcetacoplan, a targeted C3 complement inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), the largest trial conducted in these populations.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.